Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Simultaneous estimation of Olmesartan Medoxomil and Indapamide in tablet dosage form by spectroscopic method
Rucha A Patel, Hasumati A Raj, Meera V Lad and Richa A Dayaramani
Rucha A Patel, Hasumati A Raj, Meera V Lad and Richa A Dayaramani
: J Pharm Drug Deliv Res
Abstract
Olmesartan medoxomil and indapamide combination is used in cardiac disease condition like hypertension. Sustain release tablet formulation comprising olmesartan, medoxomil and indapamide. Patent for formulation is patented in china by Ministry of cardiovascular disease institute and patent for treatment for hypertension is patented in Japan. Olmesartan medoxomil was approved in USFDA on April, 2002 at New York and indapamide was approved in Lipha pharmaceutical institute on July 1998. Extensive literature survey related spectroscopy, high performance liquid chromatography, high performance thin layer chromatography, Reverse phase high performance liquid chromatography DAD method for estimation of Olmesartan medoxomil and Indapamide. Here thirteen analytical methods available for olmesartan medoxomil and twenty six analytical methods available for olmesartan medoxomil and its combination. And four analytical methods available for Indapamide, and nine analytical methods available for indapamide and its combination, seven analytical methods available for stability study for olmesartan, three analytical methods available for stability study for indapamide with other combination and no analytical method found for indapamide alone and for combination of olmesartan medoxomil and Indapamide, which indicates the need for analytical method development for Olmesartan medoxomil and Indapamide. Here attempt was made to develop and validate a sensitive, reproducible and specific spectroscopy method for Olmesartan medoxomil and Indapamide combination
Biography
